share_log

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for Pegunigalsidase Alfa

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for Pegunigalsidase Alfa

Chiesi 全球貨幣罕見疾病和 protalix biotherapeutics 宣佈歐洲藥品管理局對 Pegunigalsidase alfa 變更申請的驗證。
PR Newswire ·  12/09 19:30
(PRNewsfoto/Chiesi Global Rare Diseases)
(PRNewsfoto/奇埃西全球罕見病)
Protalix BioTherapeutics, Inc. (PRNewsfoto/Protalix BioTherapeutics, Inc.,Chiesi Global Rare Diseases)
protalix biotherapeutics, inc. (PRNewsfoto/protalix biotherapeutics, inc., 奇埃西全球罕見病)
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論